Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

Labels of all extended-release stimulants indicated for ADHD -- including certain formulations of amphetamine and ...

A mum has been left "skint" after forking out nearly £2,500 on weight loss jabs - but says "being skinny is worth the price ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...